Kelleen M Bosch, DO
Obstetrics/Gynecology · Fresno
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
- Since medical school
- 23 years
- Graduated 2003
Offices
4 locations · Community Foundation Medical Group · 282 clinicians in this group
Hospitals listed: Clovis Community Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bosch’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Clovis Community Medical CenterClovis, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Community Medical Centers, which runs 4 hospitalsPatients rate it 3 of 5 · 80% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (12.1 to 17.7) · 421 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.692, Oct 2024 – Sep 2025
See every measure and the patient survey for Clovis Community Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 6 the same, 1 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (12.1 to 17.7) · 421 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.692 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.97 (0.04 to 1.89) · 1,840 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.16 (0.86 to 1.45) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 217.06 (167.45 to 266.67) · 84 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 13.4 · 161 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14 · 507 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 798 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 336 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 3,771 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 8,649 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.08 to 0.46) · 9,146 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.46 (1.47 to 5.45) · 1,654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.19 (0.61 to 3.78) · 387 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.18 (0.7 to 3.66) · 1,578 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 13.47 (7.08 to 19.87) · 374 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.99 (1.37 to 8.61) · 379 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.04) · 405 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.8 (0.23 to 1.38) · 8,198 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 90 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.651 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.922 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.449 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.509 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 210 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 23 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -1.5 · 152 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 58.4 · 556 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18 · 769 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 802 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (4 to 7.4) · 421 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.2 · 91 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 93 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 200 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.8 to 15.6) · 2,398 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 720 cases | No different | Jan 2024 – Dec 2024 |
What patients said (441 patients answered, 26% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 80% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 69% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 52% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$27,283
Medicare paid this office $27,283 for 138 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 57 | $5,389 | $67 |
| Return visit (30+ min) | 42 | $4,616 | $96 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 20 | $3,586 | $179 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 46 | $1,837 | $40 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $1,666 | $88 |
See all 9 services
| Short return visit (20+ min) | 57 | $5,389 | $67 |
| Return visit (30+ min) | 42 | $4,616 | $96 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 20 | $3,586 | $179 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 46 | $1,837 | $40 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 19 | $1,666 | $88 |
| New patient visit (30+ min) | 18 | $1,620 | $90 |
| Complete ultrasound scan of pelvis | 18 | $1,597 | $89 |
| New patient visit (45+ min) | 11 | $1,490 | $135 |
| Urinalysis, manual test | 12 | $44 | $3 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | – | – | 13 | 17 | – | 20 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
138 Original Medicare patients in 2024. Average age 70 · Women 100% · Health risk score 0.81. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 72% · Diabetes 21% · Coronary heart disease 18% · Cancer 18% · Depression 18% · Chronic kidney disease 15% · Atrial fibrillation 9%.
The office billed $199,713, Medicare allowed $34,888 and paid $27,283; for 306 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 138 | 306 | 70 | 0.81 | $199,713 | $27,283 |
| 2023 | 185 | 385 | 70 | 0.83 | $145,014 | $31,152 |
| 2022 | 218 | 487 | 70 | 0.77 | $236,060 | $39,957 |
| 2021 | 135 | 310 | 70 | 0.77 | $140,869 | $25,137 |
| 2020 | 134 | 270 | 71 | 0.94 | $73,926 | $18,877 |
| 2019 | 186 | 543 | 71 | 0.96 | $112,299 | $28,935 |
| 2018 | 169 | 416 | 69 | 0.99 | $119,143 | $28,170 |
| 2017 | 171 | 375 | 71 | 1.10 | $82,526 | $23,361 |
| 2016 | 131 | 386 | 71 | 0.91 | $86,400 | $26,260 |
| 2015 | 113 | 329 | 69 | 0.79 | $70,378 | $22,728 |
| 2014 | 119 | 319 | 69 | 0.80 | $66,939 | $24,020 |
| 2013 | 108 | 270 | 68 | 0.87 | $68,187 | $24,395 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Short return visit (20+ min) | 68 | $7,046 | $72 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 68 | $2,776 | $41 |
| Return visit (30+ min) | 20 | $2,444 | $102 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 18 | $2,291 | $100 |
| New patient visit (30+ min) | 22 | $1,764 | $80 |
| New patient visit (45+ min) | 12 | $1,652 | $138 |
| Complete ultrasound scan of pelvis | 17 | $1,648 | $82 |
| New patient visit (15+ min) | 26 | $1,513 | $58 |
| Short return visit | 25 | $1,326 | $46 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $879 | $46 |
2022: 11 services
| Short return visit (20+ min) | 84 | $8,505 | $65 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 89 | $3,630 | $41 |
| New patient visit (30+ min) | 41 | $3,210 | $78 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 17 | $3,173 | $187 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 29 | $3,013 | $89 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 39 | $1,777 | $46 |
| Return visit (30+ min) | 17 | $1,553 | $91 |
| Complete ultrasound scan of pelvis | 16 | $1,417 | $89 |
| Short return visit | 17 | $879 | $40 |
| New patient visit (15+ min) | 12 | $632 | $53 |
| Limited ultrasound scan of pelvis | 15 | $570 | $38 |
2021: 10 services
| Short return visit (20+ min) | 57 | $6,131 | $70 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 13 | $2,192 | $169 |
| Return visit (30+ min) | 21 | $2,103 | $100 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 46 | $1,898 | $41 |
| New patient visit (45+ min) | 13 | $1,661 | $128 |
| New patient visit (30+ min) | 18 | $1,604 | $89 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,513 | $95 |
| Short return visit | 22 | $1,246 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 25 | $1,155 | $46 |
| Limited ultrasound scan of pelvis | 14 | $535 | $38 |
2020: 7 services
| Short return visit (20+ min) | 55 | $3,975 | $56 |
| New patient visit (30+ min) | 24 | $2,049 | $85 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $1,848 | $42 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $1,488 | $106 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 22 | $1,014 | $46 |
| Short return visit | 14 | $951 | $31 |
| Limited ultrasound scan of pelvis | 12 | $498 | $42 |
2019: 7 services
| Short return visit (20+ min) | 75 | $6,295 | $57 |
| New patient visit (30+ min) | 43 | $3,334 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 74 | $2,987 | $40 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 37 | $1,690 | $46 |
| Return visit (30+ min) | 13 | $1,085 | $77 |
| Short return visit | 21 | $988 | $33 |
| Automated urinalysis test | 11 | $32 | $2 |
2018: 11 services
| Short return visit (20+ min) | 76 | $6,508 | $55 |
| Return visit (30+ min) | 27 | $2,382 | $79 |
| New patient visit (30+ min) | 31 | $2,370 | $76 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 12 | $2,167 | $181 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 54 | $2,115 | $39 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 17 | $1,907 | $100 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $880 | $46 |
| New patient visit (15+ min) | 13 | $802 | $62 |
| Limited ultrasound scan of pelvis | 14 | $567 | $40 |
| Short return visit | 15 | $472 | $29 |
| Urinalysis, manual test | 34 | $161 | $3 |
2017: 9 services
| Short return visit (20+ min) | 50 | $3,906 | $51 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 75 | $2,886 | $38 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 12 | $1,529 | $96 |
| New patient visit (30+ min) | 17 | $1,457 | $86 |
| Short return visit | 34 | $1,361 | $31 |
| Return visit (30+ min) | 19 | $1,246 | $66 |
| New patient visit (15+ min) | 12 | $537 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 11 | $500 | $45 |
| Urinalysis, manual test | 30 | $127 | $3 |
2016: 8 services
| Short return visit (20+ min) | 52 | $4,285 | $50 |
| New patient visit (30+ min) | 28 | $2,232 | $80 |
| Short return visit | 31 | $1,760 | $33 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 15 | $1,557 | $92 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 39 | $1,537 | $39 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 25 | $1,174 | $47 |
| Limited ultrasound scan of pelvis | 15 | $563 | $38 |
| Urinalysis, manual test | 36 | $140 | $3 |
2015: 7 services
| New patient visit (45+ min) | 30 | $3,680 | $123 |
| Short return visit (20+ min) | 39 | $3,429 | $49 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 12 | $2,598 | $217 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 34 | $1,342 | $39 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 28 | $1,316 | $47 |
| Short return visit | 19 | $937 | $30 |
| Urinalysis, manual test | 39 | $157 | $3 |
2014: 7 services
| New patient visit (45+ min) | 43 | $5,309 | $123 |
| Short return visit (20+ min) | 51 | $4,501 | $53 |
| Biopsy of lining of uterus and/or removal of polyp using an endoscope | 11 | $2,369 | $215 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 34 | $1,318 | $39 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 27 | $1,250 | $46 |
| Return visit (30+ min) | 11 | $1,142 | $82 |
| Urinalysis, manual test | 32 | $123 | $3 |
2013: 6 services
| New patient visit (45+ min) | 39 | $4,765 | $122 |
| Short return visit (20+ min) | 45 | $3,513 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 26 | $1,007 | $39 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 19 | $894 | $47 |
| Short return visit | 17 | $880 | $33 |
| Urinalysis, manual test | 13 | $45 | $3 |
Medicaid work
$82 in 2024
Medicaid paid $82 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 14 | $82 |
| 2024 | 14 | 1 | 14 | $82 |
| 2023 | 35 | 2 | 14 | $994 |
See the largest Medicaid services in earlier years
2023
| Cesarean delivery | 14 | $994 |
| Prenatal care, at-risk enhanced service; antepartum management | 21 | $0 |
Drugs they prescribed that Part D paid
$13,906
Pharmacies billed $13,906 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
156 generic and 14 brand-name prescriptions · $13,906 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 39 | $4,342 | $59 |
| Ibuprofen | 12 | $42 | $3 |
Year by year
| 2024 | 170 | 79 | None | 8% | $13,906 |
| 2023 | 98 | 49 | None | 13% | $12,606 |
| 2022 | 158 | 81 | None | 11% | $14,404 |
| 2021 | 146 | 71 | None | 24% | $21,384 |
| 2020 | 145 | 52 | None | 17% | $16,446 |
| 2019 | 110 | 47 | None | 32% | $12,450 |
| 2018 | 100 | 45 | None | 22% | $7,734 |
| 2017 | 123 | 52 | 12% (15) | 34% | $11,341 |
| 2016 | 172 | 57 | 6% (11) | 40% | $21,667 |
| 2015 | 201 | 63 | 8% (16) | None | $16,780 |
| 2014 | 103 | 48 | None | 35% | $10,199 |
| 2013 | 118 | 48 | None | 31% | $9,071 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Estradiol | 38 | $4,270 | $112 |
| Estradiol-Norethindrone Acetat | 11 | $803 | $73 |
2022: 3 drugs
| Estradiol | 60 | $5,531 | $92 |
| Clobetasol Propionate | 12 | $341 | $28 |
| Ibuprofen | 11 | $28 | $3 |
2021: 3 drugs
| Estradiol | 60 | $7,776 | $130 |
| Prempro | 14 | $5,367 | $383 |
| Clobetasol Propionate | 11 | $327 | $30 |
2020: 3 drugs
| Estradiol | 39 | $6,314 | $162 |
| Prempro | 13 | $4,133 | $318 |
| Amitriptyline | 14 | $118 | $8 |
2019: 3 drugs
| Prempro | 12 | $4,503 | $375 |
| Estradiol | 18 | $3,305 | $184 |
| Nitrofurantoin Mono-Macro | 19 | $727 | $38 |
2018: 2 drugs
| Nitrofurantoin Mono-Macro | 21 | $616 | $29 |
| Ibuprofen | 11 | $30 | $3 |
2017: 2 drugs
| Estrace | 15 | $4,090 | $273 |
| Nitrofurantoin Mono-Macro | 30 | $1,372 | $46 |
2016: 2 drugs
| Estrace | 30 | $7,970 | $266 |
| Nitrofurantoin Mono-Macro | 29 | $1,736 | $60 |
2015: 5 drugs
| Estrace | 20 | $4,388 | $219 |
| Premarin | 15 | $3,974 | $265 |
| Nitrofurantoin Mono-Macro | 39 | $1,950 | $50 |
| Microgestin | 12 | $199 | $17 |
| Ibuprofen | 14 | $61 | $4 |
2014: 2 drugs
| Premarin | 11 | $2,463 | $224 |
| Estrace | 14 | $2,332 | $167 |
2013: 3 drugs
| Toviaz | 11 | $3,813 | $347 |
| Fluconazole | 15 | $80 | $5 |
| Naproxen | 12 | $56 | $5 |
Money from drug and device companies
$793 in 2025
| 2025 | 14 | 48 | None | $793 |
| 2024 | 10 | 25 | None | $534 |
| 2023 | 15 | 28 | None | $587 |
| 2022 | 16 | 45 | None | $747 |
| 2021 | 10 | 36 | None | $626 |
| 2020 | 12 | 38 | None | $710 |
| 2019 | 12 | 33 | $14 | $711 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | None | $192 | 13 payments
|
| Exeltis USA | Slynd | $183 | 16 payments
|
| Astellas Pharma US | Veozah | $125 | 2 payments
|
| MIMEDX Group | None | $46 | 2 payments
|
| Sumitomo Pharma America | Myfembree | $42 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Mirena | $28 | 1 payment
|
See all 48 published payments
| Exeltis USA | Meals · 2025-12-23 | Slynd | $21 |
| Exeltis USA | Meals · 2025-12-23 | Slynd | $1 |
| Mayne Pharma Commercial | Meals · 2025-12-16 | None | $7 |
| MIMEDX Group | Meals · 2025-11-19 | None | $26 |
| Astellas Pharma US | Meals · 2025-11-18 | Veozah | $25 |
| Evofem Biosciences | Meals · 2025-11-18 | Phexxi | $5 |
| Exeltis USA | Meals · 2025-11-06 | Slynd | $10 |
| Mayne Pharma Commercial | Meals · 2025-11-01 | None | $4 |
| Exeltis USA | Meals · 2025-10-27 | Slynd | $14 |
| Exeltis USA | Meals · 2025-10-27 | Slynd | $4 |
| Sumitomo Pharma America | Meals · 2025-10-15 | Myfembree | $19 |
| Mayne Pharma Commercial | Meals · 2025-10-08 | None | $28 |
| Exeltis USA | Meals · 2025-10-02 | Slynd | $11 |
| Sage Therapeutics | Meals · 2025-09-15 | Zurzuvae | $25 |
| Supernus Pharmaceuticals | Meals · 2025-09-15 | Qelbree | $25 |
| Exeltis USA | Meals · 2025-09-04 | Slynd | $6 |
| Exeltis USA | Meals · 2025-09-04 | Slynd | $6 |
| Mayne Pharma Commercial | Meals · 2025-09-02 | None | $20 |
| Lilly USA | Meals · 2025-08-19 | Mounjaro | $19 |
| Mayne Pharma Commercial | Meals · 2025-07-15 | None | $15 |
| Exeltis USA | Meals · 2025-07-10 | Slynd | $6 |
| Exeltis USA | Meals · 2025-07-10 | Slynd | $9 |
| Mayne Pharma Commercial | Meals · 2025-06-26 | None | $26 |
| MIMEDX Group | Meals · 2025-06-13 | None | $20 |
| Organon | Meals · 2025-06-12 | Nexplanon | $19 |
| Sumitomo Pharma America | Meals · 2025-05-30 | Myfembree | $23 |
| Mayne Pharma Commercial | Meals · 2025-05-22 | None | $8 |
| Hologic Sales and Service | Meals · 2025-05-14 | Aptima | $24 |
| Exeltis USA | Meals · 2025-05-07 | Slynd | $13 |
| Mayne Pharma Commercial | Meals · 2025-04-28 | None | $23 |
| Exeltis USA | Meals · 2025-04-23 | Slynd | $20 |
| Evofem Biosciences | Meals · 2025-04-17 | Phexxi | $5 |
| Evofem Biosciences | Meals · 2025-04-17 | Phexxi | $5 |
| Mayne Pharma Commercial | Meals · 2025-04-15 | None | $6 |
| Exeltis USA | Meals · 2025-04-03 | Slynd | $12 |
| Exeltis USA | Meals · 2025-03-11 | Slynd | $16 |
| Shield Therapeutics | Meals · 2025-03-05 | Accrufer | $19 |
| Mayne Pharma Commercial | Meals · 2025-03-04 | None | $27 |
| Exeltis USA | Meals · 2025-02-26 | Slynd | $18 |
| Evofem Biosciences | Meals · 2025-02-26 | Phexxi | $6 |
| Mayne Pharma Commercial | Meals · 2025-02-25 | None | $4 |
| Astellas Pharma US | Education · 2025-02-18 | None | $100 |
| Mayne Pharma Commercial | Meals · 2025-02-06 | None | $17 |
| Exeltis USA | Meals · 2025-01-30 | Slynd | $16 |
| CooperSurgical | Meals · 2025-01-21 | Paragard T 380a | $18 |
| Evofem Biosciences | Meals · 2025-01-10 | Phexxi | $6 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-08 | Mirena | $28 |
| Mayne Pharma Commercial | Meals · 2025-01-08 | None | $5 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $534
| Hologic Sales and Service | Acessa Provu System | $137 | 3 payments
|
| Mayne Pharma Commercial | None | $83 | 6 payments
|
| Evofem Biosciences | None | $69 | 4 payments
|
| Sumitomo Pharma America | Myfembree | $63 | 3 payments
|
| CooperSurgical | Paragard T 380a | $61 | 3 payments
|
| Agile Therapeutics | Twirla | $44 | 2 payments
|
| Daiichi Sankyo | Injectafer | $24 | 1 payment
|
| Shield Therapeutics | Accrufer | $23 | 1 payment
|
| Sage Therapeutics | Zurzuvae | $18 | 1 payment
|
| Organon | Nexplanon | $13 | 1 payment
|
2023: $587
| Shield Therapeutics | Accrufer | $85 | 4 payments
|
| AbbVie | Lo Loestrin Fe | $73 | 3 payments
|
| Mayne Pharma Commercial | Nextstellis | $65 | 4 payments
|
| Sumitomo Pharma America | Myfembree | $63 | 3 payments
|
| CooperSurgical | Paragard T 380a | $59 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Mirena | $41 | 2 payments
|
| OptumHealth Care Solutions | Vivify Health Care Team Portal | $39 | 1 payment
|
| Pfizer | Premarin | $30 | 2 payments
|
| Hologic Sales and Service | Acessa Provu System | $27 | 1 payment
|
| Agile Therapeutics | Twirla | $23 | 1 payment
|
| Baxter Healthcare | Adept | $18 | 1 payment
|
| Evofem Biosciences | Phexxi | $17 | 1 payment
|
| Daiichi Sankyo | Injectafer | $16 | 1 payment
|
| Organon | Nexplanon | $16 | 1 payment
|
| Astellas Pharma US | Veozah | $14 | 1 payment
|
2022: $747
| Abbvie | Oriahnn | $175 | 9 payments
|
| TherapeuticsMD | Annovera | $123 | 10 payments
|
| Myovant Sciences | Myfembree | $122 | 8 payments
|
| Daiichi Sankyo | Injectafer | $48 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Mirena | $40 | 2 payments
|
| Hologic | Myosure Tissue Removal Device | $37 | 1 payment
|
| Pfizer | Premarin | $36 | 2 payments
|
| Organon | Nexplanon | $24 | 3 payments
|
| Aspira Women's Health | Ova1 | $24 | 1 payment
|
| Meditrina | Aveta | $20 | 1 payment
|
| Agile Therapeutics | Twirla | $19 | 1 payment
|
| Mayne Pharma | None | $18 | 1 payment
|
| Qiagen | Quantiferon-Tb Gold Plus | $17 | 1 payment
|
| Becton Dickinson and | Bd Onclarity | $16 | 1 payment
|
| Avanos Medical | On-Q* Pump and Accessories | $14 | 1 payment
|
| Evofem Biosciences | Phexxi | $14 | 1 payment
|
2021: $626
| AbbVie | Lo Loestrin Fe | $321 | 19 payments
|
| Daiichi Sankyo | Injectafer | $89 | 5 payments
|
| TherapeuticsMD | Annovera | $48 | 3 payments
|
| Myovant Sciences | Myfembree | $46 | 2 payments
|
| Hologic | Thinprep 2000 Processor | $25 | 1 payment
|
| Evofem Biosciences | Phexxi | $25 | 2 payments
|
| Roche Diagnostics | Cobas 6800 System | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Mirena | $19 | 1 payment
|
| Pfizer | Myfembree | $17 | 1 payment
|
| Organon | Nexplanon | $17 | 1 payment
|
2020: $710
| AbbVie | Humira | $256 | 10 payments
|
| TherapeuticsMD | Annovera | $118 | 10 payments
|
| Daiichi Sankyo | Injectafer | $71 | 4 payments
|
| DySIS Medical | Ultra 2.0 | $53 | 1 payment
|
| Lupin | Solosec | $47 | 3 payments
|
| Allergan | Lo Loestrin Fe | $42 | 2 payments
|
| Avanos Medical | On-Q* Pump and Accessories | $32 | 2 payments
|
| Hologic | Thinprep | $31 | 2 payments
|
| Roche Diagnostics | MD Cobas Instruments and Reagents | $24 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $14 | 1 payment
|
| Pfizer | Premarin | $11 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $11 | 1 payment
|
2019: $711
| Hologic | Cervical Cancer Screening | $168 | 4 payments
|
| Daiichi Sankyo | Injectafer | $136 | 9 payments
|
| AbbVie | Orilissa | $94 | 6 payments
|
| Bard Access Systems | Progel | $71 | 1 payment
|
| Allergan | Lo Loestrin Fe | $57 | 3 payments
|
| Roche Diagnostics | MD Cobas Instruments and Reagents | $48 | 3 payments
|
| Ethicon US | Surgicel Powder | $42 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $31 | 2 payments
|
| Kci USA | Prevena | $19 | 1 payment
|
| Pfizer | Premarin | $17 | 1 payment
|
| Avion Pharmaceuticals | Prenate Mini | $14 | 1 payment
|
| Vermillion | Ova1 | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 85.8 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1811105414
- Licence
- CA 20A9211
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207VX0000X (207VX0000X)
- Mailing address
- 1374 E Alluvial Ave, Fresno, CA, 93720
- NPI first listed
- 2007-05-18
- NPI last updated
- 2013-09-18
This is when the NPI record was last certified, not a medical board exam.